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Abstract We detected alternative splicing of the mouse brain possibly generate further heterogeneity rather than the above 
type ryanodine receptor (RyR3) mRNA. The splicing variant was three types. In the case of IPsR, its subtypes are expressed in a 
located in the transmembrane segment. The non-splicing type tissue-specific or developmental manner due to various alter- 
(RyR3-II) included a stretch of 341 bp, and that of the 13th native splicing of mRNAs in the N-terminal and modulatory 
codon was stop codon TAA. Reverse transcription-polymerase regions [14,15]. Indeed, alternative splicing of RyR1 and 
ehain reaetion (RT-PCR) analysis shows that RyR3-II mRNA RyR2 mRNAs has also been reported [5,16]. However, no 
was expressed in various peripheral tissues and brain at all alternative splicing of RyR3 mRNA has been reported. In 
developmental stages. However, interestingly, the splicing type the present study, we detected alternative splicing of mouse 
(RyR3-I) mRNA was detected only in the cerebrum. These RyR3 mRNA which was localized in the transmembrane s g- 
findings suggest hat the splicing variants RyR3-I and RyR3-1I ment. We also investigated the distribution of the splicing 
may generate functional differences of RyR3 in a tissue-specific pattern in various tissues and at various developmental stages 
manner, by means of reverse transcription-polymerase chain reaction 
Key words." Ryanodine receptor; Calcium release channel; (RT-PCR) analysis. The results show that the splicing pattern 
Mouse brain; Alternative splicing; RT-PCR was in a tissue-specific manner. 
2. Materials and methods 
1. Introduction 2.1. Cloning and sequencing ofmouse cDNAs for the splicing (RyR3-I) 
and non-splicing (RyR3-11) types of RyR3 
The ryanodine receptor (RyR) is one of the major Ca 2+ A newborn BALB/c mouse brain cDNA library in phage ~gtll 
release channels, which is activated by Ca 2+, causing Ca 2+ (Stratagene) was used for PCR amplification of the transmembrane 
- segment in the mouse RyR3 gene. The oligonucleotide primers for 
induced Ca 2+ release (CICR) from intracellular Ca 2+ stores PCR were designed in the previous tudy, as follows: sense primer 
[1-3]. RyR proteins are formed from 550-565 kDa monomers, 3A, 5'-TTCATCCTGCTGTTTTATAAGGT-3', and antisense primer 
and to date three isoforms are known to be encoded by dif- 3B, 5'-CAGATGAAGCATTTGGTCTCCAT-3'; corresponding to 
nucleotide numbers 13724-13746 and 14860-14882 of human 
ferent genes: the skeletal muscle type (RyRI)  [4], the cardiac RyR1, respectively [4,17]. The buffer for PCR comprised 50 mM 
type (RyR2) [5,6], and the brain type (RyR3) [7,8]. RyRs are KC1, 10 mM Tris-HC1, pH 8.3, 0.25 mM each dCTP, dGTP, dTTP 
expressed in many tissues, but their expression patterns are and dATP, 80 nM oligonucleotide primers, 2 units of Ampli-Taq 
different [8-11]. Early studies revealed the localization of polymerase (Perkin Elmer), and 5 ~tl of cDNA, in a final volume 50 
RyRs: RyR1 primarily to skeletal muscle, RyR2 to heart lal. The samples were subjected to 5 cycles of 1 min at 94°C, 1 min at 
37°C, and 2 min at 72°C, and then 40 cycles of 1 min at 94°C, 2 min 
and brain, and RyR3 to brain and some peripheral tissues, at 50°C, and 2 min at 72°C, with a final extension step at 72°C for 
However, recent studies involving RNase protection analysis 7 min. The PCR product was resolved by electrophoresis on a 2% 
or reverse transcription-polymerase chain reaction (RT-PCR) agarose gel, and 1.5 kbp, 1.2 kbp and 1156 bp fragments were visua- 
analysis revealed that all the RyRs are widely expressed in lized by staining with ethidium bromide. Then the PCR products were 
immediately subcloned into TA plasmids (Invitrogen), and both 
brain and peripheral tissues; RyR1 is also expressed in cere- strands of the cloned PCR products containing the three types of 
bellar Purkinje cells, RyR2 is the major isoform in almost all fragments were sequenced with a model 377A DNA Sequencer 
parts of the central nervous system, and RyR3 is expressed in (ABI) according to the manufacturer's instructions. The sequence 
some restricted areas of the brain, especially the corpus stria- analysis showed that the 1156 bp fragment was mouse RyR3 
tus, thalamus and hippocampus [9-13]. cDNA, the 1.2 kbp fragment mouse RyR2 cDNA, and the 1.5 kbp 
fragment mouse RyR3 cDNA with an insertion of 341 bp [10]. 
The alternative splicing of mRNAs of the RyRs genes may Furthermore, a new pair of oligonucleotide primers was designed to 
sequence the 614 bp fragment including the 341 bp insertion, as fol- 
lows: sense primer SP1F, 5'-AGGTGATCAACAAGTATGGA-Y, 
*Corresponding author. Fax: (81) (878) 98-4136. and antisense primer SP1R, 5'-CAACAGATGAGCAGCAAAGA- 
3'. We repeated the cloning and sequencing steps more than five times 
Abbreviations." RyRs, ryanodine receptors; RT-PCR, reverse tran- to rule out sequencing errors due to PCR amplification. 
scription-polymerase chain reaction; IPzR, inositol 1,4,5-tripbosphate 
receptor; CICR, Ca2+-induced Ca 2+ release; E, embryonic day; NB, 2.2. Sequencing ofgenomic DNA around the splicing site 
newborn To determine the sequence of genomic DNA around the splicing 
site, genomic DNA from adult BALB/c mouse liver was purified with 
The nucleotide sequences reported in this paper have been submitted to a RapidPrep Genomic DNA Isolation Kit for Cells and Tissues 
the GenBank~/EMBL/DDBJ Data Bank with accession numbers (Pharmacia Biotech) according to the manufacturer's instructions. 
D85590 and D85591. The PCR amplification of the genomic DNA was carried out through 
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42 cycles of 1 min at 94°C, 2 min at 45°C, and 2 min at 72°C, with a El5 to 15 weeks), the RT-PCR assay with primers SP1F and 
final extension step at 72°C for 7 min, oligonucleotides SP1F and SP1R was utilized, following Southern hybridization analysis. 
SP1R being used as PCR primers. The 940 bp fragment of the PCR 
product was subcloned into plasmids and sequenced according to the The 100 base probe for Southern hybridization was designed 
same methods as above, so as to be common to RyR3-I and RyR3-II, being designed 
from the sequence of upstream of the splicing site. The lengths 
2.3. RT-PCR assay for expression of RyR3-I and RyR3-H of signals were expected to be 273 bp for RyR3-I and 614 bp 
BALB/c mice, from embryos to adults (embryonic day 15 (El5), 
newborn (NB), 1, 2, 3, 8, and 15 weeks) were prepared for analysis of for the RyR3-II. The results howed that RyR3-I and RyR3- 
the expression level of RyR3-I and RyR3-II mRNAs in the brain, and II mRNAs were expressed in the whole brain at all stages. 
20-day-old BALB/c mice were prepared for distribution analysis of Densitometric analysis revealed the expression of RyR3-II 
RyR3-I and RyR3-II in some tissues (cerebrum, cerebellum, skeletal mRNA was less than that of RyR3-I at all stages (Fig. 2A). 
muscles, heart, lung, liver, spleen, kidney and peripheral blood). 
mRNAs from mouse tissues were purified with a Quick-Prep Micro 
mRNA Purification Kit (Pharmacia Biotech), and each purified 3.3. Expression of RyR3-Iand RyR3-H in a tissue-specific 
mRNA was converted into cDNA with a Ready-To-Go T-Primed manner 
First-Strand Kit (Pharmacia Biothech) according to the manufac- To determine the tissue distribution of RyR3-I and RyR3- 
turer's instructions. The PCR amplification of cDNA was carried II, the RT-PCR assay was utilized by the same method as 
out through 30 cycles of 1 min at 94°C, 2 rain at 43°C, and 2 rain 
described above (Fig. 2B). As a result, 614 bp signals of at 72°C, with a final extension step at 72°C for 7 min, oligonucleotides 
SP1F and SP1R being used as PCR primers. [~-Actin cDNA of brains RyR3-II were detected in cerebrum, cerebellum, skeletal mus- 
at all stages was amplified as a control to determine the quantities of cle, heart, liver, spleen, kidney and peripheral blood, but not 
cDNA under the same conditions as described above. The PCR prod- lung, the signal in the pancreas was being weaker than in the 
ucts were electrophoresed on 2% agarose gels and then transferred to other tissues. To our surprise, 273 bp signals, which represent 
Hybond N+ membranes (Amersham). The 100 base oligonucleotide 
probes used were designed by the sequence of mouse RyR3 cDNA RyR3-I, were not detected in any tissues except cerebrum. 
upstream of the splicing site, as follows: SP2, GATCTCTATGGAG- 
CAGAGCGCATCGCTGAACTCCTGGGTTT GGACAAAAATG- 4. Discussion 
CCCTTGACTTTAGCCCAGTAGAAGAGGCCA AAGCAGAGG- 
CAGCATCTC. The probe was labelled by the 3'-end labelling 
method with [y-32P]ATP, using a Megalabel Kit (TaKaRa). Hybridi- RyR is one of the Ca 2+ release channels from intracellular 
zation was performed in a hybridization buffer comprising 10xDen- stores in skeletal and cardiac muscles, and functions as CICR 
hardt's solution, 6xSSC, 0.1% SDS, and 50 ~tg/ml salmon sperm [18-23]. To date, three isoforms are known to be encoded by 
DNA overnight at 65°C. Next, the membranes were washed w i th  different genes [4-8,24]. Alternative splicing of mRNAs could 
6xSSC at room temperature, and 2XSSC and 0.5xSSC at 65°C also generate subtypes rather than the three RyR isoforms in 
(1 xSSC: 150 mM NaC1, 15 mM sodium citrate, pH 7.0). Autoradi- 
ography was then performed. Densitometric analysis of signals was a tissue-specific or developmental manner. Indeed, alternative 
performed with a BAS-1000 (Fuji Film). splicing of the RyR1 and RyR2 genes has already been dem- 
onstrated [5,15,16,25]. In the present study, we detected alter- 
native splicing of mouse RyR3 mRNA. RyR3-II included 
3. Results stop codon TAA in the transmembrane domain between M2 
and M3. Furthermore, the splicing variant was in a tissue- 
3.1. Sequence of  the 341 bp insertion of  RyR3-H specific manner. 
By sequence analysis of the 1156 bp and 1.5 kbp fragments, The sequences of RyR3 and the other RyRs exhibit 70% 
which were PCR amplified using primers 3A and 3B, we iden- homology [8,26], and alignment of the amino acid sequences 
tiffed a splicing variant of mouse RyR3 cDNA. In addition, a revealed significant similarity between RyR and IPaR [8,27- 
new pair of oligonucleotide primers SP1F and SP1R were 29]. It has also been reported that there are four hydrophobic 
designed to sequence around the splicing site. The inclusion segments (M1-M4) in the carboxy-terminal region of RyR3. 
and exclusion of 341 bp generated two variants RyR3-I and Since, in particular, the M3 and M4 segments show remark- 
RyR3-II, respectively (Fig. 1A). The 341 bp splicing site was able amino acid sequence similarity to the corresponding re- 
located between M2 and M3 in the transmembrane segment gion of IP3R, this region may contribute to the Ca 2+ release 
of the RyR3 gene. The 13th codon of inclusion site was coded mechanism which is common to both intracellular Ca 2+ re- 
stop codon TAA, and the sequences on the 5' and 3' sides lease channels [8]. The four highly hydrophobic transmem- 
were GT and AG, respectively (Fig. 1B). brane segments in RyR3-I can not be conserved in RyR3-II 
We next analysed the genomic organization around the because of a stop codon between M2 and M3. These findings 
splicing site by PCR amplification of the mouse RyR3 genom- suggest that the function of RyR3-II as a Ca 2+ release channel 
ic DNA with primers SP1F and SP1R, and a 940 bp fragment may be different from that of RyR3-I and the other RyRs. 
was amplified and sequenced. Comparison of the sequences of Some agents are known that affect RyR, such as ryanodine, 
the cDNA and genomic DNA revealed that the 940 bp ge- caffeine, ruthenium red, cyclic adenosine diphosphoribose, a 
nomic DNA fragment between SP1F and SP1R contains three metabolite of nicotinamide adenine dinucleotide [30-33]. 
exons and two introns, 341 and 326 bp, respectively. The However, the sensitivity to ryanodine or caffeine of RyR3 is 
sequence of the 341 bp intron was the same as that of the known to differ from that of RyR1 or RyR2, and vice versa. 
splicing region, and that of the 326 bp intron was also in Giannini et al. [7] demonstrated that RyR3 in mink lung 
accordance with the GT/AG rule. epithelial cells was insensitive to caffeine. Hakamata et al. 
[8] reported that RyR3 was insensitive to caffeine but sensitive 
3.2. Expression of RyR3-1 and RyR3-H in the brain at various to ryanodine. A recent study involving myocytes from dyspe- 
developmental stages dic mice lacking RyR1 revealed that RyR3 functions as a 
To determine the expression level of RyR3-I and RyR3-II CICR channel sensitive to caffeine and ryanodine, but 
mRNAs in the brain at various developmental stages (from RyR3 had the lowest Ca 2+ sensitivity among the members 
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of the mammalian RyR family [34]. These findings suggest A 
that differences in the functioning of RyR3 as a Ca 2+ release 
channe lor  thesens i t i v i ty tosomeagentsmaybeduetoa  ~ ~ "~ ~ "~ ~ ~ 
structural difference between RyR3 and the other RyRs. r.r.1 ,., 
Also, RyR3-I I  which has an incomplete channel region, may RyR3-1I 
contribute to the lower function of RyR3 as a Ca 2+ release 614 bp 
channel. 
RyR3 is known to be widely expressed not only in the RyR3-I 
central nervous system but also in peripheral tissues such as 273 bp 
mammalian skeletal muscle, heart, lung, stomach, spleen, pan- fl -aetin 
creas, intestine, kidney, and human Jurkat T-cells [8,10,11,17]. 
We also determined the tissue distributions of RyR3-II  and 
B RyR3-I mRNAs by RT-PCR assay, the RyR3-II  mRNA -~,%1 
_m being detected in the cerebrum, cerebellum, skeletal muscle, ~ 
SPIF 
_ii.Ii ! 341 bp 326 bp SPIR SPI F ~; 
RyR3- I I  [~  V/ / / / / / /A  I RyR3-I @ .... . . . . . . .  
I { ....... 
SP1R Fig. 2. Autoradiograms after blot hybridization analysis of RT-PCR 
products from mouse brain, from El5 to 15 weeks (A), and periph- 
eral tissues (B). RyR3 cDNA from brains at several developmental 
* stages (El5 15 weeks) and peripheral tissues were amplified with .m ~ ~--COOH 
NH2 ~ ' • primers SP1F and SFIR. The signals of PCR products of 614 and 
Ml M2 M3 M4 I I 273 bp, which correspond to RyR3-II and RyR3-I, respectively, are 
transmembranedomain indicated. The signal of 13-actin at each developmental stage is indi- 
cated at the bottom. 
B 
SP1F ~ heart, liver, spleen, kidney and peripheral blood. However, to 
NAGGTGA,rC~u~CAAGTATGGW"~AGATCTCTATGC_AGCAC~.GCGCATCGCTC~,ACTC our surprise, RyR3-I mRNA was only detected in the cere- 
K v i N K Y G D L Y G A E a I A E ~, brum. These findings suggest hat these splicing variants occur 
CTCW.~GTTT~AC~TGCCCTTGACTTTAGCCCAGTA~GAC:43CC~GCA in a tissue-specific manner; RyR3-II  may be a superior type in 
L G L D K N A L D F S P V E E A K A 
GAGGCAGCATCTCTGGTGTCAT(~ACAGATCTGAGGAGCTCAAGTCCAAGTGG peripheral tissues, RyR3-I may be a neuronal type of RyR3, 
E A A s L v s w IY R s E E L K s K w and the mechanism of Ca 2+ release via RyR3 may differ be- 
~ .a~AGATAANTCCTTTGTTTCCCATTCCTCTCCAGTGAGCTAGANGTA tween brain and peripheral tissues. In addition, the coex- R - istence of the two splicing variants of RyR3 mRNA in the 
AAGCATGTC TTTTGTTCTC TTGCAAATTAGGAGAGAAT GCTTTCAAGGATTTC 
~ATGGGCAATCAATCTGTGTGCCCAAAGACTAATGTCTTGGGGAGCATGATTCA~ brain suggests that RyR-I  and RyR3-II  might interact and 
~ACCATTCTGTCTCTCTGGAAAATCTATAT~%.TTTGATi~k.~AC~TC.~.C42TG'I contribute to regulate intracellular Ca 2+ release in neurons. 
3TTTATGTTATTAACCTTAAG~'IWCCCCCTTCATTAAACAGTT'nd~'CT'n'AC The densitometric analysis indicated that the expression of 
[ATTGACATTTCTa~GTTATGA.~ACTAT'I~TTCCTCTTT~2TAAGTTCCATCG RyR3-II  mRNA was much less than that of RyR3-I. 
ACAT GAAGTA C CATATT TGGAAGC TAC-C~TGGTTTTCACTGACAACTCCTTTC 
TCTACCTTC-CCTGGTACACAACCATGTCTGTCC~CACTACAACAACTTCT Although the ryanodine-binding study indicated that a ryano- 
TCTTTGCTGCTCATCTGTTG l dine-binding site was present in liver microsomes, and ryano- 
-~ dine binding to the liver endoplasmic reticulum was inhibited 
SP1R by caffeine [35], RyR3 mRNA was not detected in liver on 
Fig. 1. (A) Schematic diagram of mouse RyR3 showing the location RT-PCR [10,11], which might be due to the low level of ex- 
of the alternative splicing site, and the splice variants RyR3-I and 
RyR3-1I. The alternatively spliced region was located between M2 pression of the RyR3 gene and protein in the liver, as sug- 
and M3 in the putative transmembrane s gment of the RyR3 gene, gested by Giannini et al. [10]. Moreover, despite the fact that 
and the inclusion and exclusion of a stretch of 341 bp generated RyR3 mRNA was detected in the skeletal and cardiac mus- 
two variants RyR3-II and RyR3-I. The expected sizes of the PCR cles, the RyR3 protein was not detected in microsomes from 
products are 273 bp for RyR3-I and 614 bp for RyR3-II by PCR these tissues by Western blot analysis [10]. However, in our 
using primers (SP1F and SP1R), respectively. Exons and the 341 bp 
inclusion of RyR3-II are shown by boxes and shaded box. (B) The study, only RyR3-II  mRNA was detected in peripheral tissues 
partial sequences of the nucleotide (top) and the deduced amino including skeletal and cardiac muscles and liver, RyR3-I 
acid (in single-letter code; bottom) of mouse RyR3-II cDNA. The mRNA not being detected. Therefore, previous studies might 
sequence of the 341 bp inclusion site (enclosed with solid lines) is have failed to detect RyR3 mRNA in the liver due to the low 
the same as that of the 341 bp intron, and is in accordance with 
the GT/AG rule. The 13th codon is a stop codon TAA (asterisk). amount of RyR3-II  mRNA.  Furthermore, differences in the 
The intron-exon boundary where interrupted by the 326 bp intron high-affinity binding of ryanodine between liver microsomes 
in genomic DNA is shown by a triangle, and sarcoplasmic reticulum [35,36] may be due to the fact that 
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RyR1, RyR2 and RyR3-II are expressed in skeletal muscle [15] Schell, M.J., Dannoff, S.K. and Ross, C.A. (1993) Brain Res. 
but only RyR3-II is expressed in the liver. Mol. Brain. Res. 17, 212-216. 
In the present study, we have demonstrated tissue-specific [16] Futatsugi, A., Kuwajima, G. and Mikoshiba, K. (1995) Biochem. 
J. 305, 373-378. 
alternative splicing of mouse RyR3 mRNA for the first time. [17] Hakamata, Y., Nishimura, S., Nakai, J., Nakashima, Y., Kita, T. 
In addition, this variant splicing may generate differences in and Imoto, K. (1994) FEBS Lett. 352, 206-210. 
its function as a Ca z+ release channel, and the coexistence of [18] Endo, M. (1977) Physiol. Rev. 57, 71-108. 
the two splicing variants in the cerebrum may contribute to [19] Fleischer, S. and Inui, M. (1989) Annu. Rev. Biophys. Biophys. 
Chem. 18, 333-364. 
the regulation of the intracellular Ca 2+ release in the central [20] Glaum, S.R., Scholz, W.K. and Miller, R.J. (1990) J. Pharmacol. 
nervous system. Exp. Ther. 253, 1293 1302. 
[21] Nabauer, M., Callewaert, G., Cleemann, L. and Morad, M. 
(1989) Science 244, 800 803. 
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